Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Saved in:
| Title: | Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. |
|---|---|
| Authors: | Yi, Zongbi1 (AUTHOR) yizongbi@163.com, Ma, Fei1 (AUTHOR) drmafei@126.com, Liu, Binliang1 (AUTHOR) liubinliang_onco@163.com, Guan, Xiuwen1 (AUTHOR) guanxiuwen@foxmail.com, Li, Lixi1 (AUTHOR) 1054983057@qq.com, Li, Chunxiao2 (AUTHOR) campuscx@163.com, Qian, Haili2 (AUTHOR) qianhaili001@163.com, Xu, Binghe1 (AUTHOR) bhxu@hotmail.com |
| Source: | BMC Cancer. 5/14/2019, Vol. 19 Issue 1, p1-9. 9p. 1 Chart, 6 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
